EnsiliTech is a recent biotech startup looking to apply our patented platform technology, Ensilication, to store and transport vaccines, antibodies, and other biopharmaceuticals, without the need for refrigeration or freezing. Having recently secured £1.2 million of funding, and with participation in numerous accelerator programmes, our mission is to deploy this technology across both human and animal healthcare sectors.
Currently, the shipment and storage of biopharmaceuticals requires a continuous network of fridges and freezers known as the cold-chain. This system is extremely costly to operate and prone to regular failures, resulting in over 50% of the vaccines being wasted. Globally, 1.5 million infants die each year from vaccine-preventable diseases, primarily in low-middle income countries, where vaccines struggle to be delivered.
Ensilication is a novel method for encasing thermally unstable biomolecules within a silica network to prevent degradation at room temperature and improves the shelf-life. The technology is designed to be applied both to existing, and new biopharmaceutical formulations. It produces thermally stable products that do not rely on cold-chain transport and storage, presenting significant cost savings, reducing wastage and increasing global accessibility to life-saving treatments and diagnostics.